Vanguard Global Advisers
KALV

Vanguard Global Advisers’s KalVista Pharmaceuticals KALV Stock Holding History

Vanguard Global Advisers’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,711
Closed -$377K – 3695
2026
Q1 		$377K Buy
+18,711
New +$302K ﹤0.01% 2164

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Global Advisers's KALV Position: Q2 2026 in Review

Vanguard Global Advisers sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 18,711 shares — an estimated $377K sold.

Vanguard Global Advisers first reported a position in KALV in Q1 2026 and held it in 1 quarter. The position peaked at $377K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Vanguard Global Advisers reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 18,711 KalVista Pharmaceuticals shares in Q2 2026, an estimated $377K.
  • Vanguard Global Advisers first reported a position in KalVista Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's KalVista Pharmaceuticals position peaked at $377K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.